MASS earnings

908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld dev

Fourth quarter 2025 revenue increased 21% compared to prior year Achieved positive Adjusted EBITDA in the fourth quarter 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025. Q4 2025 and Full Year 2025 Financial Highlights Revenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024 Revenue of $56.2 million for the full year 2025, increasing 18% compared to the full year 2024 Recurring revenue was $19.5 million for the full

908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the fourth quarter and full year 2025 before market open on Tuesday, March 3, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its si

Year-to-date revenue increased 16% while Adjusted EBITDA loss improves 53% quarter over quarter 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended September 30, 2025. "We are pleased with our year-to-date progress as we continue to build a more predictable and profitable business and bring our 908 Devices 2.0 vision to life," said Kevin J. Knopp, CEO and Co-founder. "Revenue for the first nine months increased 16%, with strong FTIR demand and with 47% of revenues coming from our U.S. state and local channel. T

908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will report financial results for the third quarter 2025 before market open on Monday, November 10, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical ana

Revenue from continuing operations grew 14% compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. "We executed with urgency and discipline in the second quarter, driving strong top-line growth while advancing key structural initiatives to strengthen our financial profile," said Kevin J. Knopp, CEO and Co-founder. "We delivered record XplorIR placements, successfully launched VipIR, and made meaningful progress on our path to profitability. These achievements reinforce our c

908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced it will report financial results for the second quarter 2025 before market open on Tuesday, August 5, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical an

Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in

At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the fourth quarter and full year 2024 before market open on Tuesday, March 4, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life

Revenue increases 17% compared to prior year, driven by recently acquired handheld products 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September 30, 2024. "While we are pleased that our revenue increased year-over-year due to our newly acquired products, our third quarter results fell short of our expectations due to challenges from the delayed FY24 federal budget, delays with advancing international contracts, and ongoing softness in the bioprocessing and life science instrumentation market," said Kevin J. Knopp, CEO and Co-founder. "Despite near-term headwinds, we

908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, November 12, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering appli

Revenue increases 16% compared to prior year, driven by newly acquired handheld products 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024. "We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently," said Kevin J. Knopp, CEO and Co-founder. "We also maintained a strong focus on operational excellence during the quarter and have begun to see early

908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering appli

First quarter 2024 product and service revenue increased 8% compared to prior year, driven by a 20% increase in handheld revenue Acquired RedWave Technology, expanding forensics product portfolio for point-of-need applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2024. "We had a solid start to the year with topline revenue of $10 million for the first quarter and continued to see robust demand for our handheld devices as applications for chemical detection and identification at the point of need gain further traction in the US and i

Adds optical spectroscopy to the company's technology platform for point-of-need applications 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR spectroscopic analyzers for rapid chemical identification of bulk materials. FTIR (Fourier Transform Infrared), an optical spectroscopy technology, is highly regarded for its specific substance identification abilities across a broad range of bulk materials. This acquisition provides 908 Devices with an expanded portfolio of handheld chemic

908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices,

Fourth quarter 2023 revenue increased 23% compared to prior year, driven by handheld revenue increasing 57% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2023. "We made solid progress in 2023 towards our objectives. We have continued to see sustained growth of our handheld devices servicing customers in their efforts to combat the ongoing crisis of counterfeit drugs and opioids. For the full year we saw 28% growth in our handheld revenue and consistent year-over-year growth each quarter. Despite near-term headwinds impacting t

908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and

908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023. "We are pleased with the step-up in our revenues from the second quarter and the positive growth trend over the past nine months, despite the challenging environment in the life sciences instrumentation and bioprocessing markets," said Kevin J. Knopp, CEO and Co-founder. "Handheld revenue grew 19% year to date and we expect that to further accelerate in the fourth quarter. This underscores the value our handheld devices bring to our customers, aiding them in enhancing public safety during t

908 Devices Inc., (NASDAQ:MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the third quarter 2023 before market open on Tuesday, November 7, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devi

Revenue increases 9% compared to prior year, driven by handheld revenue growth of 27% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended June 30, 2023. "We delivered solid results in the second quarter driven by robust demand for our handheld devices and strong recurring revenue," said Kevin J. Knopp, CEO and Co-founder. "We continue to capture opportunities for our flagship handheld device, which is being increasingly recognized as the standard for trace detection of fentanyls and synthetic opioids. We are also excited about an upcoming product launch that

908 Devices Inc., (NASDAQ:MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the second quarter 2023 before market open on Tuesday, August 8, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devic

Q1 2023 revenue increases 14% compared to prior year with recurring revenue growing 67% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2023. "I am pleased to see the strong recurring value that our technology brings to our customers by providing analysis at the point of need," said Kevin J. Knopp, CEO and Co-founder of 908 Devices. "We are seeing robust demand for our handheld devices while we continue to focus on broadening our portfolio in bioprocessing. We are uniquely positioned with a diversified suite of devices serving forensics and biop

908 Devices Inc., (NASDAQ:MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2023 before market open on Tuesday, May 9, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices,

Full Year 2022 revenue increases 11% compared to prior year with desktop revenue increasing 25% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2022. "While we are pleased with the progress made against our long-term objectives in 2022, as anticipated, we experienced protracted sales cycles and more conservative capital budgets during the fourth quarter, which will likely persist through the first half of 2023," said Kevin J. Knopp, CEO and Co-founder. "Despite these near-term headwinds, we started 2023 off strong with the launch

908 Devices Inc., (NASDAQ:MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2022 before market open on Tuesday, March 7, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and des

Q3 2022 revenue increases 26% over prior year, with gross margin of 59% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September 30, 2022. "We were pleased with our results for the third quarter as we continue to support our customers' critical-to-life applications. We also executed the strategic acquisition of TRACE Analytics, which provides in-line testing of critical parameters in the bioreactor and enables us to fast-track development of our on-line REBEL technology," said Kevin J. Knopp, CEO and Co-founder. "During the quarter, we began to

908 Devices Inc., (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices Inc. (NASDAQ:MASS) is democratizing laboratory mass spectrometry with it

Q2 2022 revenue increases 34% over prior year, with gross margin of 60% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, 2022. "We are pleased with our first half 2022 performance, in which our revenue grew 40%, including desktop revenue growth of 52%. I am encouraged by the continued enthusiasm we are seeing across our end markets for real-time analysis at the point-of-need," said Kevin J. Knopp, CEO and Co-founder. "Excitingly, we have acquired TRACE Analytics, providing us with on-line aseptic bioreactor sampling and biosensor technolo

908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH, based in Braunschweig, Germany, a provider of on-line analysis and sampling systems for biotech applications. 908 Devices expects the acquired technology to enable its mass spec devices as on-line bioprocess monitors. Founded in 2003, TRACE Analytics develops on-line aseptic sampling systems and novel biosensors for bioreactor monitoring and control. Their validated technology, in single-use and reusable configurations, is applied in mammalian cell culture and microb

908 Devices Inc., (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 9, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices Inc. (NASDAQ:MASS) is democratizing laboratory mass spectrometry with its

Q1 2022 revenue increases 50% over prior year with Desktop revenue in BioPharma growing 68% 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022. "We had a strong start to the year with revenue growing 50% over the prior year period. We made tangible progress against our goals as we continued to enable our customers with rapid chemical and biochemical analysis when and where they need it," said Kevin J. Knopp, CEO and Co-founder. "From global biopharma sites to prominent local events in our communities, like the Boston Marathon, our dev

908 Devices Inc., (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is democratizing laboratory mass spectrometry with its simple handheld and d

908 Devices Inc. (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices Inc. (NASDAQ:MASS) is democratizing laboratory mass spectromet

Sequential revenue growth of more than 50% compared to Q2 2021 Year-to-date product and service revenue growth of 36% compared to the same period of 2020 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September 30, 2021. "We delivered solid results this quarter as we continued to expand our installed base, deepen our relationships and broaden the capabilities of our platforms to deliver even more value," said Kevin J. Knopp, CEO and Co-founder. "In September, we hosted our first integrated user meeting where customers discussed the impact of ou

908 Devices Inc., (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2021 before market open on Thursday, November 4, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is democratizing laboratory mass spectrometry with its simple handheld

Increased 2021 revenue guidance projects 54% annual revenue growth at the midpoint of the range 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, 2021. "I am incredibly proud of our team's progress this quarter as we continue to execute on our growth strategy. We have made important strides across our business and are looking forward to continuing this momentum into the second half of the year," said Kevin J. Knopp, CEO and Co-founder. "We now expect revenue to grow more than 50% this year as we expand our global presence and continue to a

BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- 908 Devices Inc., (NASDAQ:MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2021 before market open on Wednesday, August 4, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices908 Devices is democratizing laboratory ma